No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in MS PATHS

被引：0
|
作者：
Ryerson, Lana Zhovtis [1 ]
Naismith, Robert T. [2 ]
Krupp, Lauren B. [1 ]
Charvet, Leigh [1 ]
Liao, Shirley [3 ]
Fisher, Elizabeth [3 ]
De Moor, Carl [3 ]
Williams, James R. [3 ]
Licata, Stephanie [3 ]
Campbell, Nolan [3 ]
机构：
[1] NYU, Dept Neurol, NYU Langone Hlth, New York, NY 10003 USA
[2] Washington Univ, Dept Neurol, St Louis, MO 14263 USA
[3] Biogen, Cambridge, MA USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1964
引用
下载
收藏
页数：3
相关论文
共 50 条
  • [1] No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in ms paths
    Zhovtis-Ryerson, L.
    Naismith, R. T.
    Krupp, L.
    Charvet, L.
    Su, R.
    Fisher, E.
    De Moor, C.
    Williams, J.
    Campbell, N.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 293 - 293
  • [2] No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS
    Ryerson, Lana Zhovtis
    Naismith, Robert T.
    Krupp, Lauren B.
    Charvet, Leigh E.
    Liao, Shirley
    Fisher, Elizabeth
    de Moor, Carl
    Williams, James R.
    Campbell, Nolan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 58
  • [3] Pharmacodynamics of natalizumab extended interval dosing in MS
    Zhovtis Ryerson, Lana
    Li, Xiaochun
    Goldberg, Judith D.
    Hoyt, Tamara
    Christensen, Angel
    Metzger, Ryan R.
    Kister, Ilya
    Foley, John
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (02):
  • [4] Lymphocyte response in standard and extended interval dosing of natalizumab
    Rafee, S.
    Kennelly, L.
    Mcguigan, C.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 170 - 170
  • [5] Modelling efficacy of natalizumab in patients who switch from standard interval dosing (SID) to extended interval dosing (EID)
    Chang, I.
    Muralidharan, K.
    Campbell, N.
    Ho, P. -R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 480 - 480
  • [6] Effectiveness of Natalizumab in Extended Dosing Interval
    Hervas, Jose Vicente
    Punet-Ortiz, Joan
    Teniente-Serra, Aina
    Mansilla, M. Jos
    Quirant-Sanchez, Bibiana
    Navarro, Juan
    Presas, Silvia
    Martinez-Caceres, Eva
    Ramo, Cristina
    NEUROLOGY, 2016, 86
  • [7] Effectiveness of natalizumab in extended dosing interval
    Ramo-Tello, C.
    Grau-Lopez, L.
    Vilaro, L.
    Segui, C.
    Delicado, S.
    Bonafont, X.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 213 - 214
  • [8] Natalizumab: extended versus standard interval dosing in the real world
    Wagner, B.
    Richter, S.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 880 - 881
  • [9] Extended interval dosing of natalizumab in MS; a New Zealand experience
    Chan, Calvin
    Siu, Ronald
    Mellsop, Nick
    Schepel, Jan
    NEUROLOGY, 2018, 90
  • [10] Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing
    Foley, John F.
    Goelz, Susan
    Hoyt, Tamara
    Christensen, Angelene
    Metzger, Ryan R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 31 : 65 - 71
12345